Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings

被引：4

作者：

Yacoub, Abdulraheem ^{[1
,2
]}

Mascarenhas, John ^{[3
]}

Mesa, Ruben A. ^{[4
]}

Kosiorek, Heidi E. ^{[5
]}

Rampal, Raajit K. ^{[6
]}

Silver, Richard T. ^{[7
]}

Salama, Mohamed E. ^{[8
]}

Siwoski, Olivia ^{[9
]}

Dueck, Amylou C. ^{[5
]}

Sandy, Lonette ^{[10
]}

McMullin, Mary Frances ^{[11
]}

Ewing, Joanne ^{[12
]}

O'Connell, Casey L. ^{[13
]}

Mead, Adam J. ^{[14
]}

De Stefano, Valerio ^{[15
]}

Weinberg, Rona Singer ^{[16
]}

Baer, Maria R. ^{[17
]}

Kessler, Craig M. ^{[18
]}

Winton, Elliott F. ^{[19
]}

Vannucchi, Alessandro M. ^{[20
,21
]}

Kremyanskaya, Marina ^{[22
]}

Vadakara, Joseph ^{[23
]}

Rosti, Vittorio ^{[24
]}

Hexner, Elizabeth O. ^{[25
]}

Rondelli, Damiano ^{[26
]}

Arcasoy, Murat O. ^{[27
]}

Rambaldi, Alessandro ^{[28
,29
]}

Ritchie, Ellen K. ^{[30
]}

Barbui, Tiziano ^{[31
]}

Kiladjian, Jean-Jacques ^{[32
]}

Harrison, Claire N. ^{[33
]}

Prchal, Josef T. ^{[34
,35
]}

Hoffman, Ronald ^{[3
]}

机构：

[1] Univ Kansas, Dept Hematol Malignancies & Cellular Therapies, Canc Ctr, Westwood, KS USA

[2] Kansas Univ, Malignant Hematol & Cellular Therapuit, Canc Ctr, Leawood, KS USA

[3] Icahn Sch Med Mt Sinai, Div Hematol Med Oncol, Tisch Canc Inst, New York, NY 10029 USA

[4] UT Hlth San Antonio MD Anderson, Mays Canc Ctr, San Antonio, TX USA

[5] Mayo Clin, Dept Biostat, Scottsdale, AZ USA

[6] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA

[7] NewYork Presbyterian Weill Cornell Med Ctr, Richard T Silver Myeloproliferat Neoplasms Ctr, New York, NY USA

[8] Mayo Med Labs, Rochester, MN USA

[9] Univ Kansas, Malignant Hematol & Cellular Therapuit, Canc Ctr, Westwood, KS USA

[10] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[11] Queens Univ, Belfast, Antrim, North Ireland

[12] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England

[13] Univ Southern Calif, Keck Sch Med, Jane Anne Nohl Div Hematol, Los Angeles, CA 90007 USA

[14] Univ Oxford, Oxford, England

[15] Univ Cattolica, Fdn Policlin Gemelli IRCCS, Ist Ematol, Rome, Italy

[16] New York Blood Ctr, New York, NY 10021 USA

[17] Univ Maryland, Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA

[18] Georgetown Univ, Med Ctr, Washington, DC 20007 USA

[19] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA

[20] Univ Florence, CRIMM, Florence, Italy

[21] Univ Florence, Ctr Res & Innovat Myeloproliferat Neoplasms, Florence, Italy

[22] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA

[23] Geisinger Med Ctr, Danville, PA 17822 USA

[24] IRCCS Policlin San Matteo Fdn, Ctr Study Myelofibrosis, Lab Biochem Biotecnol & Adv Diag, Pavia, Italy

[25] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[26] Univ Illinois, Div Hematol Oncol, Chicago, IL USA

[27] Duke Univ, Sch Med, Durham, NC USA

[28] Univ Milan, Bergamo, Italy

[29] Azienda Socio Sanit Terr Papa Giovanni XX, Bergamo, Italy

[30] Weill Cornell Med Coll New York Presbyterian, New York, NY USA

[31] ASST Papa Giovanni XXIII, FROM Res Fdn, Bergamo, Italy

[32] Hop St Louis, Paris, France

[33] Guys & St Thomas NHS Fdn Trust, Dept Clin Haematol, London, England

[34] Univ Utah, Div Hematol, Salt Lake City, UT USA

[35] Huntsman Canc Ctr, Salt Lake City, UT USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-124865

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2943

引用

页数：5

共 50 条

[41] Single-Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia Who Are Either Hydroxyurea-Resistant or Intolerant: Final Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial
Yacoub, Abdulraheem
Mascarenhas, John
Kosiorek, Heidi Elizabeth
Prchal, Josef T.
Berenzon, Dmitriy
Baer, Maria R.
Ritchie, Ellen K.
Silver, Richard T.
Kessler, Craig M.
Winton, Elliott F.
Finazzi, Maria Chiara
Rambaldi, Alessandro
Vannucchi, Alessandro M.
Leibowitz, David S.
Rondelli, Damiano
Arcasoy, Murat O.
Catchatourian, Rosalind
Vadakara, Joseph
Rosti, Vittorio
Hexner, Elizabeth
Kremyanskaya, Marina
Orellana, Alicia
Sandy, Lonette
Tripodi, Joseph
Najfeld, Vesna
Salama, Mohamed E.
Weinberg, Rona Singer
Rampal, Raajit K.
Mesa, Ruben A.
Goldberg, Judith D.
Dueck, Amylou C.
Hoffman, Ronald
[J]. BLOOD, 2017, 130
[42] Polycythemia vera and essential thrombocythemia of intermediate-age: A real-life, multicenter analysis of first-line treatment approach
Sobieralski, Patryk
Bieniaszewska, Maria
Bolkun, Lukasz
Sacha, Tomasz
Muzalewska-Wolska, Magdalena
Homenda, Wojciech
Bartkowiak, Lucja K.
Smith, Justyna
Rymko, Marcin
Jachalska, Anna
Mital, Andrzej R.
Prejzner, Witold
Zaucha, Jan
[J]. ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2024,
[43] Histologic improvement following treatment with once weekly pegylated interferon alfa-2a (Pegasys™) and thrice weekly interferon alfa-2a (Roferon™)in patients with chronic hepatitis C and compensated cirrhosis.
Balart, LA
Lee, SS
Schiffman, M
Reindollar, R
Minuk, G
Pockros, P
Hoffman, J
Depamphilis, J
[J]. GASTROENTEROLOGY, 2000, 118 (04) : A961 - A961
[44] Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys)
Okikiolu, Jumoke
Woodley, Claire
Cadman-Davies, Llywelyn
O'Sullivan, Jennifer
Radia, Deepti
Garcia, Natalia Curto
Harrington, Patrick
Kordasti, Shahram
Asirvatham, Susan
Sriskandarajah, Priya
Saunders, Jamie
Saha, Chandan
Sanchez, Irene
deLavallade, Hugues
McLornan, Donal P.
Harrison, Claire N.
[J]. LEUKEMIA RESEARCH REPORTS, 2023, 19
[45] Histologic improvement following treatment with once weekly pegylated interferon alfa-2a (Pegasys™) and thrice weekly interferon alfa-2a (Roferon™) in patients with chronic hepatitis C without cirrhosis.
Reddy, KR
Shiffman, M
Reindollar, R
Fried, M
Pockros, P
Hoffman, J
DePamphilis, J
[J]. GASTROENTEROLOGY, 2000, 118 (04) : A945 - A945
[46] A phase II trial of pegylated interferon α-2b therapy for polycythemia vera and essential thrombocythemia -: Feasibility, clinical and biologic effects, and impact, on quality of life
Samuelsson, Jan
Hasselbalch, Hans
Bruserud, Oystein
Temerinac, Snezana
Brandberg, Yvonne
Merup, Mats
Linder, Olle
Bjorkholm, Magnus
Pahl, Heike L.
Birgegard, Gunnar
[J]. CANCER, 2006, 106 (11) : 2397 - 2405
[47] USE OF PEGYLATED INTERFERON ALFA-2A (PEG-IFN) IN THE SECOND LINE TREATMENT OF CHRONIC MYELOPROLIFERATIVE NEOPLASMS (NMP): EXPERIENCE OF THE CATALAN INSTITUTE OF ONCOLOGY (ICO)
Quinones, T.
Sagues, M.
Osca, G.
Estrada, N.
Boque, C.
Vallansot, R.
Lopez-Brunso, M.
Coll, R.
Tuset, E.
Gallardo, D.
Xicoy, B.
Zamora, L.
[J]. HAEMATOLOGICA, 2019, 104 : 303 - 303
[48] Variation of allelic load of JAK2 V617F in patients with polycythemia vera and essential thrombocythemia treated in first-line with hydroxyurea
Marchay, Nathalie
[J]. HEMATOLOGIE, 2011, 17 (02): : 111 - 112
[49] Pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a or alfa-2b with ribavirin in treatment naive patients with genotype 1 chronic hepatitis C
Di Bisceglie, AM
Rustgi, VK
Thuluvath, P
Davis, M
Ghalib, R
Lyons, MF
Ondovik, MS
Lopez-Talavera, JC
[J]. HEPATOLOGY, 2004, 40 (04) : 734A - 734A
[50] Ribavirin Impairs Salivary Gland Function in Hepatitis C Patients During Combination Treatment With Pegylated Interferon Alfa-2a
Aghemo, Alessio
Rumi, Maria Grazia
Monico, Sara
Banderali, Matteo
Russo, Antonio
Ottaviani, Francesco
Vigano, Mauro
D'Arnbrosio, Roberta
Colombo, Massimo
[J]. HEPATITIS MONTHLY, 2011, 11 (11) : 919 - 925

← 1 2 3 4 5 →